CD274 and neoplasm: Pembrolizumab uses the PD-L1 IHC 22C3 pharmDx (Dako) assay to test membranous staining of PD-L1 on tumor cells, with TPS <1% scored as no expression, 1–49% as low expression, and ≥50% as a high expression [35].